158 related articles for article (PubMed ID: 27125186)
1. Favourable response to rituximab by an ocular adnexal primary lymphoma.
Luque Valentin-Fernandez ML; Alvarez Rodríguez F; Rodríguez Jiménez I
Arch Soc Esp Oftalmol; 2016 Nov; 91(11):539-542. PubMed ID: 27125186
[TBL] [Abstract][Full Text] [Related]
2. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
[TBL] [Abstract][Full Text] [Related]
3. MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab.
Tektonidou MG
Lupus; 2010 Sep; 19(10):1243-5. PubMed ID: 20501524
[TBL] [Abstract][Full Text] [Related]
4. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland.
Heinz C; Merz H; Nieschalk M; Mueller-Miny H; Koch P; Heiligenhaus A
Br J Ophthalmol; 2007 Nov; 91(11):1563-4. PubMed ID: 17947275
[No Abstract] [Full Text] [Related]
6. Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma.
Demirci H; Kauh CY; Rajaii F; Elner VM
Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S70-S71. PubMed ID: 26950471
[TBL] [Abstract][Full Text] [Related]
7. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
Celiker H; Toker E; Kaygusuz Atagunduz I
Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab.
Morgensztern D; Rosado MF; Serafini AN; Lossos IS
Leuk Lymphoma; 2004 Jun; 45(6):1275-8. PubMed ID: 15360012
[TBL] [Abstract][Full Text] [Related]
9. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
10. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
Nückel H; Meller D; Steuhl KP; Dührsen U
Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
[TBL] [Abstract][Full Text] [Related]
12. Conjunctival Lymphoma.
McGrath LA; Ryan DA; Warrier SK; Coupland SE; Glasson WJ
Eye (Lond); 2023 Apr; 37(5):837-848. PubMed ID: 35882984
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.
Annibali O; Chiodi F; Sarlo C; Cortes M; Quaranta-Leoni FM; Quattrocchi C; Bianchi A; Bonini S; Avvisati G
Biomed Res Int; 2015; 2015():895105. PubMed ID: 26425558
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
15. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
16. Conjunctival extranodal marginal zone B-cell lymphoma with crystal-storing histiocytosis.
Mittal R; Damato B; Coupland SE
Acta Ophthalmol; 2015 Nov; 93(7):e602-3. PubMed ID: 25988528
[No Abstract] [Full Text] [Related]
17. Follicular lymphoma of the ocular adnexal region: a nation-based study.
Rasmussen PK; Ralfkiaer E; Prause JU; Sjö LD; Specht L; Rossing HH; Siersma VD; Heegaard S
Acta Ophthalmol; 2015 Mar; 93(2):184-91. PubMed ID: 25125069
[TBL] [Abstract][Full Text] [Related]
18. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
[No Abstract] [Full Text] [Related]
19. [Case of a bilateral MALT lymphoma of the lacrimal sac treated only medically].
Abdelkhalek R; Ahmimech J; Mouzariae Y; El Idrissi A; El Hamichi S; Messaoudi R; Bargach T; Reda K; Oubaaz A
J Fr Ophtalmol; 2015 Dec; 38(10):e237. PubMed ID: 26616299
[No Abstract] [Full Text] [Related]
20. [The preliminary observation of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma].
Yang JP; Pang X; Zhang K; Wang LL; Zhu Y
Zhonghua Yan Ke Za Zhi; 2020 Nov; 56(11):839-845. PubMed ID: 33152842
[No Abstract] [Full Text] [Related]
[Next] [New Search]